B. Metzler seel. Sohn & Co. AG Acquires 4,285 Shares of Inspire Medical Systems, Inc. (NYSE:INSP)

B. Metzler seel. Sohn & Co. AG boosted its holdings in shares of Inspire Medical Systems, Inc. (NYSE:INSP) by 46.9% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 13,425 shares of the company’s stock after buying an additional 4,285 shares during the quarter. B. Metzler seel. Sohn & Co. AG’s holdings in Inspire Medical Systems were worth $2,489,000 at the end of the most recent quarter.

Other institutional investors also recently bought and sold shares of the company. Clearbridge Investments LLC increased its holdings in shares of Inspire Medical Systems by 24.6% during the 4th quarter. Clearbridge Investments LLC now owns 16,349 shares of the company’s stock valued at $3,031,000 after acquiring an additional 3,231 shares during the last quarter. Arrowstreet Capital Limited Partnership boosted its position in Inspire Medical Systems by 1,587.1% during the fourth quarter. Arrowstreet Capital Limited Partnership now owns 35,294 shares of the company’s stock worth $6,543,000 after purchasing an additional 33,202 shares during the period. Cornercap Investment Counsel Inc. bought a new stake in Inspire Medical Systems during the fourth quarter worth approximately $439,000. Pictet Asset Management Holding SA grew its holdings in Inspire Medical Systems by 14.2% during the fourth quarter. Pictet Asset Management Holding SA now owns 4,298 shares of the company’s stock valued at $797,000 after purchasing an additional 536 shares during the last quarter. Finally, New Age Alpha Advisors LLC bought a new position in shares of Inspire Medical Systems in the fourth quarter valued at approximately $453,000. 94.91% of the stock is currently owned by institutional investors.

Insider Activity at Inspire Medical Systems

In related news, insider Randy Ban sold 25,584 shares of the stock in a transaction that occurred on Thursday, February 13th. The stock was sold at an average price of $183.50, for a total transaction of $4,694,664.00. Following the sale, the insider now directly owns 7,259 shares in the company, valued at $1,332,026.50. This represents a 77.90 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CTO John Rondoni sold 583 shares of Inspire Medical Systems stock in a transaction on Tuesday, February 11th. The shares were sold at an average price of $170.49, for a total value of $99,395.67. Following the completion of the transaction, the chief technology officer now owns 10,424 shares of the company’s stock, valued at approximately $1,777,187.76. The trade was a 5.30 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 26,225 shares of company stock valued at $4,806,530 over the last quarter. 4.10% of the stock is owned by company insiders.

Analysts Set New Price Targets

A number of research firms recently issued reports on INSP. Robert W. Baird lowered their target price on shares of Inspire Medical Systems from $252.00 to $248.00 and set an “outperform” rating on the stock in a research note on Tuesday, February 11th. KeyCorp reaffirmed an “overweight” rating and issued a $234.00 price target (down from $236.00) on shares of Inspire Medical Systems in a research report on Friday, January 24th. Piper Sandler cut their price objective on Inspire Medical Systems from $260.00 to $233.00 and set an “overweight” rating for the company in a research report on Monday, February 10th. Stifel Nicolaus lowered their target price on Inspire Medical Systems from $200.00 to $190.00 and set a “hold” rating on the stock in a report on Tuesday, January 21st. Finally, Morgan Stanley cut their price target on Inspire Medical Systems from $230.00 to $220.00 and set an “overweight” rating for the company in a report on Tuesday, February 11th. Three analysts have rated the stock with a hold rating and seven have given a buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $226.70.

Inspire Medical Systems Trading Down 1.0 %

Shares of INSP stock opened at $157.74 on Wednesday. Inspire Medical Systems, Inc. has a 12 month low of $123.00 and a 12 month high of $257.40. The company has a market capitalization of $4.69 billion, a P/E ratio of 91.18, a P/E/G ratio of 2.86 and a beta of 1.48. The stock has a 50 day moving average of $178.23 and a two-hundred day moving average of $189.28.

Inspire Medical Systems (NYSE:INSP) last posted its quarterly earnings results on Monday, February 10th. The company reported $1.15 earnings per share for the quarter, topping analysts’ consensus estimates of $0.74 by $0.41. Inspire Medical Systems had a net margin of 6.67% and a return on equity of 8.19%. Sell-side analysts predict that Inspire Medical Systems, Inc. will post 2.16 earnings per share for the current fiscal year.

About Inspire Medical Systems

Inspire Medical Systems, Inc, a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA.